Cargando…
Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
Cabergoline-associated valvulopathy (CAV) is defined by the echocardiographic triad of moderate or severe regurgitation, valvular thickening and restricted valvular motion. While it is a well-described complication of dopamine agonist therapy in Parkinson’s disease, only three convincing cases of CA...
Autores principales: | Hayes, Annabelle G, Shirazi, Masoumeh G, Thiyagarajah, Anand, Torpy, David J, De Sousa, Sunita M C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305698/ https://www.ncbi.nlm.nih.gov/pubmed/37434646 http://dx.doi.org/10.1530/EO-22-0086 |
Ejemplares similares
-
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
por: Khare, Shruti, et al.
Publicado: (2017) -
Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation
por: Yedinak, Chris G., et al.
Publicado: (2014) -
Cabergoline Treatment in Invasive Giant Prolactinoma
por: Alsubaie, Sadeem, et al.
Publicado: (2014) -
The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening
por: Caputo, Carmela, et al.
Publicado: (2018) -
Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline
por: Ghadirian, Hesam, et al.
Publicado: (2018)